EIM
VKTX icon

Essex Investment Management’s Viking Therapeutics VKTX Stock Holding History

Essex Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50,000
Closed -$344K – 513
2019
Q3 		$344K Sell
50,000
-63,177
-56% -$469K 0.05% 318
2019
Q2 		$939K Sell
113,177
-45,164
-29% -$386K 0.13% 228
2019
Q1 		$1.57M Sell
158,341
-104,764
-40% -$877K 0.23% 141
2018
Q4 		$2.01M Buy
+263,105
New +$3.15M 0.32% 94

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Essex Investment Management's VKTX Position: Q4 2019 in Review

Essex Investment Management sold out of Viking Therapeutics (VKTX) in Q4 2019, closing a stake of 50,000 shares — an estimated $344K sold.

Essex Investment Management first reported a position in VKTX in Q4 2018 and held it in 4 quarters. The position peaked at $2.01M in Q4 2018. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

  • Essex Investment Management reported no remaining Viking Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Essex Investment Management sold 50,000 Viking Therapeutics shares in Q4 2019, an estimated $344K.
  • Essex Investment Management first reported a position in Viking Therapeutics in Q4 2018 and held it in 4 quarters.
  • Essex Investment Management's Viking Therapeutics position peaked at $2.01M in Q4 2018.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on Essex Investment Management's 13F filing for Q4 2019, filed 10 Feb 2020.